secwatch.observer — SEC 8-K summary
======================================

Issuer:     Humacyte, Inc. (HUMA)
CIK:        0001818382
Form:       8-K
Filed at:   2026-03-19T23:59:59+00:00
Accession:  0001104659-26-031780
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Humacyte reports preliminary FY2025 revenue $2M, 61 Symvess units; suspends ATM
-------------------------------------------------------------------------------

- Preliminary FY2025: cash $50.9M, total revenue $2.0M (product $1.4M), 61 Symvess unit sales.
- Received $1.48M minimum purchase commitment from KSA entity for Symvess; exclusive negotiations through July 2026.
- Filed Marketing Authorization Application in Israel for Symvess in vascular trauma; also pursuing hospital-by-hospital access.
- Suspended $60M ATM program effective March 19, 2026; no further sales unless new prospectus filed.
- Risk factors updated; accumulated deficit $702M as of Sep 2025, company expects need for additional funding.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/0001104659-26-031780-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818382/000110465926031780/tm269106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-031780

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer